Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03518125 · ClinicalTrials.gov registry record · Phase 2
BARDA Securing Anthrax Immunity For the Elderly
A Phase 2 study, sponsored by Biomedical Advanced Research and Development Authority.
- Completed
- Registry status
- Phase 2
- Development phase
- 305
- Enrollment target
NCT03518125 is a Phase 2 study that has completed, run by Biomedical Advanced Research and Development Authority. The registered enrollment target is 305 participants.
The verdict
NCT03518125, a Phase 2 study, has completed, sponsored by Biomedical Advanced Research and Development Authority.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 305 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable health.
Interventions
- BIOLOGICAL AV7909
- BIOLOGICAL BioThrax
- DRUG Sodium chloride injection USP, 0.9% (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2018-05-09 |
| Est. Completion | 2019-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03518125
The ClinicalTrials.gov registry entry for NCT03518125 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomedical Advanced Research and Development Authority, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AV7909 is the first listed.
NCT03518125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03518125 about?
NCT03518125 is a clinical study titled "BARDA Securing Anthrax Immunity For the Elderly". This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable health.
What is the current status of trial NCT03518125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 305 participants. The study started on 2018-05-09. Estimated completion is 2019-12-09.
What interventions are being tested in trial NCT03518125?
The interventions under investigation include: AV7909 (BIOLOGICAL), BioThrax (BIOLOGICAL), Sodium chloride injection USP, 0.9% (placebo) (DRUG).
Who is sponsoring clinical trial NCT03518125?
This trial is sponsored by Biomedical Advanced Research and Development Authority, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.